News Cytokinetics, Incorporated Deutsche Boerse AG

Equities

KK3A

US23282W6057

Market Closed - Deutsche Boerse AG Other stock markets 15:49:17 2024-05-24 EDT			5-day change	1st Jan Change
44.4 ^EUR	-2.20%		-19.27%	-40.00%

05-23	Raymond James Adjusts Price Target on Cytokinetics to $70 From $92, Maintains Outperform Rating	MT
05-23	Sector Update: Health Care Stocks Flat to Lower Premarket Thursday	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Raymond James Adjusts Price Target on Cytokinetics to $70 From $92, Maintains Outperform Rating	05-23	MT
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday	05-23	MT
Nvidia Earnings Fuel Investor Optimism, Driving Premarket Gains for US Equity Futures	05-23	MT
Needham Adjusts Price Target on Cytokinetics to $72 From $108, Maintains Buy Rating	05-23	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday as Tech Stocks Rally on NVIDIA Earnings	05-23	MT
Stocks in motion: e.l.f Beauty soars along with Nvidia	05-23
Top Premarket Decliners	05-23	MT
Cytokinetics Prices $500 Million Common Stock Offering	05-23	MT
Cytokinetics Announces Pricing of Public Offering of Common Stock	05-22	AQ
Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline	05-22	MT
Cytokinetics Plans $500 Million Common Stock Offering -- Shares Drop After Hours	05-22	MT
Cytokinetics Announces Proposed Public Offering of Common Stock	05-22	AQ
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline	05-22	AQ
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology	05-17	AQ
Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors	05-17	CI
Transcript : Cytokinetics, Incorporated - Shareholder/Analyst Call	05-15
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024	05-15	AQ
Transcript : Cytokinetics, Incorporated - Special Call	05-13
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress	05-13	AQ
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine	05-13	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cytokinetics, Incorporated Deutsche Boerse AG

Equities

KK3A

US23282W6057

Summary

Filters